CHDI Foundation | GenomeWeb

CHDI Foundation

The partners will develop biomarkers for potential use in drug development targeting the disease. 

NEW YORK (GenomeWeb News) – Evotec said today that the CHDI Foundation has extended and expanded the two parties' collaboration on Huntington's disease research through 2017.

NEW YORK (GenomeWeb) – The Structural Genomics Consortium and the CHDI Foundation have struck an agreement to discover and characterize new drug targets for Huntington's disease and to make their findings available for use by academic researchers and pharmaceutical and biotechnology companies.

NEW YORK (GenomeWeb News) – KineMed said this week that it has extended its collaboration with the CHDI Foundation on research into biomarkers for Huntington's disease.

NEW YORK (GenomeWeb) – KineMed and CHDI Foundation today said they are extending their collaboration to characterize and track the pathogenesis of Huntington's disease and to evaluate possible therapeutic interventions.

KineMed has entered into a collaboration with Isis Pharmaceuticals and CHDI Foundation that will use KineMed's biomarker platform in support of Isis' antisense therapeutics program for Huntington's disease.

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.

NEW YORK (GenomeWeb News) – GNS Healthcare and the CHDI Foundation jointly announced today that they will collaborate on the development of a data-driven computer model of Huntington's disease intended to drive personalized medicine research.

NEW YORK (GenomeWeb News) – Thomson Reuters' Intellectual Property & Science business announced a deal with the CHDI Foundation to develop systems biology tools for Huntington's disease.

NEW YORK (GenomeWeb News) – KineMed and CHDI Foundation announced late on Monday a partnership to use KineMed's technology to investigate the turnover rates of huntingtin protein, which plays a crucial role in the pathogenesis of Huntington's disease.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.